X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pexa-Vec (pexastimogene devacirepvec) is a vaccinia virus based oncolytic immunotherapy is being evaluated in combination with cemiplimab for the treatment of metastatic or unresectable renal cell carcinoma.
Lead Product(s): Pexastimogene devacirepvec,Cemiplimab
Therapeutic Area: Oncology Product Name: Pexa-Vec
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: SillaJen, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
REGN1979 (odronextamab) is a novel, off-the-shelf, CD20×CD3 bispecific antibody, which is being evaluated for the treatment of relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma.
Lead Product(s): Odronextamab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: REGN1979
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Through the termination, Intellia opted out of a partnership with Regeneron to develop a factor IX gene editing therapy, for the treatment of hemophilia A and B.
Lead Product(s): CRISPR-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Intellia Therapeutics
Deal Size: $420.0 million Upfront Cash: $100.0 million
Deal Type: Termination March 22, 2024
Details:
Praluent (alirocumab) inhibits the binding of PCSK9 to the LDL receptor. It is now approved for the treatment of pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.
Lead Product(s): Alirocumab
Therapeutic Area: Genetic Disease Product Name: Praluent
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Under the agreement, GENESIS will commercialize the approved product of Regeneron, Libtayo (cemiplimab), which is a PD-1 inhibitor. It is used for the treatment of advanced basal cell carcinoma, cutaneous squamous cell carcinoma and non-small cell lung cancer.
Lead Product(s): Cemiplimab
Therapeutic Area: Oncology Product Name: Libtayo
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: GENESIS Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2024
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. It is being evaluated for the treatment of chronic obstructive pulmonary disease with type 2 inflammation.
Lead Product(s): Dupilumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Dupixent
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
REGN5458 (linvoseltamab), an investigational bispecific antibody designed to bridge B-cell maturation antigen on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation. It is being evaluated for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Linvoseltamab
Therapeutic Area: Oncology Product Name: REGN5458
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 pathways and is not an immunosuppressant. It is approved for the treatment of chronic spontaneous urticaria.
Lead Product(s): Dupilumab
Therapeutic Area: Immunology Product Name: Dupixent
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
REGN5458 (linvoseltamab) is an investigational BCMAxCD3 bispecific antibody. It is being evaluated in phase 3 clinical trials for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Linvoseltamab
Therapeutic Area: Oncology Product Name: REGN5458
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
Under the acquisition, Regeneron will have full development and commercialization rights to its pipeline of investigational novel immune cell therapies, including Abecma (idecabtagene vicleucel) along with its discovery and clinical manufacturing capabilities.
Lead Product(s): Idecabtagene Vicleucel
Therapeutic Area: Oncology Product Name: Abecma
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: 2Seventy Bio
Deal Size: Undisclosed Upfront Cash: $5.0 million
Deal Type: Acquisition January 30, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
